Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation

PURPOSE: Brain metastasis (BM) is associated with impaired quality of life and increased mortality. The study aimed to compare BM risk after erlotinib administration and chemotherapy in stage IIIB/IV pulmonary adenocarcinoma patients harboring epidermal growth factor receptor (EGFR) mutation. PATIEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Xing, Ligang, Meng, Xue, Yue, Jinbo, Meng, Xiangjiao, Xie, Peng, Li, Xiaolin, Kong, Li, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751907/
https://www.ncbi.nlm.nih.gov/pubmed/26917973
http://dx.doi.org/10.2147/OTT.S100105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751907/
https://www.ncbi.nlm.nih.gov/pubmed/26917973
http://dx.doi.org/10.2147/OTT.S100105

Ejemplares similares